Enhancing treatment outcomes through targeted testing

Stimulants, or sympathomimetic amines, increase central nervous system activity and can be used to treat and manage attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. While some stimulants have pharmacological applications, others are categorized as Scheduled I compounds by the Drug Enforcement Agency and are often sold illicitly and abused. As a result, many professional practice guidelines recommend compliance testing in patients prescribed stimulant medications.

Stimulant test menu

Targeted screening

Our targeted, high-resolution mass spectrometry screening panel identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test. Utilizing mass spectrometry in place of traditional immunoassay testing not only increases specificity, but eliminates false positives caused by cross-reactivity with other medications. By reducing the need for additional confirmatory testing, the targeted stimulant screen saves time and money while enabling clinicians to accurately detect stimulant use and monitor compliance.

Key testing

Comprehensive monitoring

Several of our comprehensive profiles include targeted stimulant screening (Mayo ID: TSTIM).

Panel testing

Key testing

  1. Five million American adults misusing prescription stimulants. National Institute on Drug Abuse. April 16, 2018. Accessed March 18, 2021.
  2. Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series).
  3. Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag. 2014;10(2):119–134

Fill out the form below and one of our specialists will be in touch.